Group 1 - Company approved the use of up to RMB 2.5 billion of idle funds for cash management, including investments in fixed-income products and time deposits [1][2] - The cash management program allows for rolling use of funds within the approved limit, with the chairman authorized to implement related matters [1] - Recent cash management activities have resulted in the maturity and recovery of certain products [2] Group 2 - Company agreed to provide a guarantee for its wholly-owned subsidiary, Hainan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd., to apply for a credit limit of RMB 1.408 billion from banks [5][6] - A maximum guarantee amount of RMB 30 million has been established under a joint liability guarantee contract with Shanghai Pudong Development Bank [7][8] - The total amount of guarantees provided by the company and its subsidiaries is RMB 1.34227 billion, with a current balance of RMB 900.898 million, representing 11.77% of the company's audited net assets for 2024 [9][10]
一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理到期收回的公告